Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working GroupPhilippe Moreau, Jean‐Luc Harousseau, Evangelos Terpos et al.|The Lancet Oncology|2021Cited by 266
Preliminary Evidence Of Anti Tumor Activity Of Selinexor (KPT-330) In a Phase I Trial Ofa First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Relapsed / Refractory Non Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)John Kuruvilla, Mansoor Raza Mirza, Martin Gutierrez et al.|Blood|2013Cited by 30
Glucarpidase for treatment of high-dose methotrexate toxicityShruti Gupta, Anthony Nicolaysen, Sarah Allison Kaunfer et al.|Blood|2025Cited by 30
A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or In Combination with Low-Dose Dexamethasone In Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and BortezomibPaul G. Richardson, Kenneth C. Anderson, David Siegel et al.|Blood|2010Cited by 7